Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal vs intramuscular haloperidol for agitation in schizophrenia
2014-001157-17Phase 3Completed
- Sponsor
- Fundació Parc Taulí
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of haloperidol in schizophrenia and agitation (2 arms), sponsored by Fundació Parc Taulí. Primary endpoint: Controlled agitation at 20 minutes. Started Jun 2014; status: completed.
02
Drugs
haloperidol
03
Conditions
schizophreniaagitation
Beyond the preview
Go deeper on 2014-001157-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001157-17.